Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis.

Acetylcholine receptor Complement Inclusion body myositis Myofiber Senescence Single nuclei

Journal

Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041

Informations de publication

Date de publication:
11 2023
Historique:
received: 23 06 2023
accepted: 19 09 2023
revised: 18 09 2023
medline: 12 10 2023
pubmed: 29 9 2023
entrez: 29 9 2023
Statut: ppublish

Résumé

Inclusion body myositis (IBM) is unique across the spectrum of idiopathic inflammatory myopathies (IIM) due to its distinct clinical presentation and refractoriness to current treatment approaches. One explanation for this resistance may be the engagement of cell-autonomous mechanisms that sustain or promote disease progression of IBM independent of inflammatory activity. In this study, we focused on senescence of tissue-resident cells as potential driver of disease. For this purpose, we compared IBM patients to non-diseased controls and immune-mediated necrotizing myopathy patients. Histopathological analysis suggested that cellular senescence is a prominent feature of IBM, primarily affecting non-myogenic cells. In-depth analysis by single nuclei RNA sequencing allowed for the deconvolution and study of muscle-resident cell populations. Among these, we identified a specific cluster of fibro-adipogenic progenitors (FAPs) that demonstrated key hallmarks of senescence, including a pro-inflammatory secretome, expression of p21, increased β-galactosidase activity, and engagement of senescence pathways. FAP function is required for muscle cell health with changes to their phenotype potentially proving detrimental. In this respect, the transcriptomic landscape of IBM was also characterized by changes to the myogenic compartment demonstrating a pronounced loss of type 2A myofibers and a rarefication of acetylcholine receptor expressing myofibers. IBM muscle cells also engaged a specific pro-inflammatory phenotype defined by intracellular complement activity and the expression of immunogenic surface molecules. Skeletal muscle cell dysfunction may be linked to FAP senescence by a change in the collagen composition of the latter. Senescent FAPs lose collagen type XV expression, which is required to support myofibers' structural integrity and neuromuscular junction formation in vitro. Taken together, this study demonstrates an altered phenotypical landscape of muscle-resident cells and that FAPs, and not myofibers, are the primary senescent cell type in IBM.

Identifiants

pubmed: 37773216
doi: 10.1007/s00401-023-02637-2
pii: 10.1007/s00401-023-02637-2
pmc: PMC10564677
doi:

Substances chimiques

Collagen 9007-34-5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

725-745

Informations de copyright

© 2023. The Author(s).

Références

Acta Neuropathol. 2022 Aug;144(2):353-372
pubmed: 35612662
Nat Rev Immunol. 2014 Dec;14(12):811-20
pubmed: 25394942
Nat Commun. 2022 Aug 16;13(1):4827
pubmed: 35974106
Nat Rev Nephrol. 2023 Jul;19(7):426-439
pubmed: 37055581
Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1194-9
pubmed: 11158616
Wiley Interdiscip Rev Dev Biol. 2016 Jul;5(4):518-34
pubmed: 27199166
Mol Metab. 2023 Jan;67:101652
pubmed: 36509362
Best Pract Res Clin Rheumatol. 2022 Jun;36(2):101761
pubmed: 35760741
Mol Med Rep. 2022 Nov;26(5):
pubmed: 36111491
Skelet Muscle. 2021 Nov 2;11(1):24
pubmed: 34727990
J Neurol Sci. 2022 Aug 15;439:120317
pubmed: 35709642
Neurology. 2014 Jul 29;83(5):426-33
pubmed: 24975859
Oncotarget. 2019 Jan 29;10(9):993-1009
pubmed: 30847027
Nat Cell Biol. 2015 Aug;17(8):1049-61
pubmed: 26147250
Cell Biosci. 2021 Mar 31;11(1):65
pubmed: 33789727
J Neuropathol Exp Neurol. 1995 Jul;54(4):581-7
pubmed: 7602331
Neuromuscul Disord. 2013 Dec;23(12):1044-55
pubmed: 24268584
EMBO Mol Med. 2013 Apr;5(4):626-39
pubmed: 23505062
Cell. 2019 Oct 31;179(4):813-827
pubmed: 31675495
Muscle Nerve. 2009 Jun;39(6):739-53
pubmed: 19291799
Cell Physiol Biochem. 2019;52(3):617-632
pubmed: 30907989
Neuropathol Appl Neurobiol. 2017 Feb;43(1):62-81
pubmed: 28075491
J Neurosci. 2010 Sep 15;30(37):12230-41
pubmed: 20844119
Trends Mol Med. 2022 Oct;28(10):850-863
pubmed: 35965205
Neurology. 2022 Mar 29;98(13):e1374-e1383
pubmed: 35131904
Ann Rheum Dis. 2023 Jun;82(6):829-836
pubmed: 36801811
Elife. 2022 Feb 28;11:
pubmed: 35225230
Immunity. 2021 May 11;54(5):1002-1021.e10
pubmed: 33761330
Nat Aging. 2022 Jul;2(7):601-615
pubmed: 36147777
EBioMedicine. 2019 Sep;47:446-456
pubmed: 31542391
Aging Cell. 2022 Nov;21(11):e13723
pubmed: 36165462
EBioMedicine. 2019 Nov;49:381-388
pubmed: 31662290
Differentiation. 2016 Sep;92(3):108-115
pubmed: 27282924
Nat Rev Rheumatol. 2019 May;15(5):257-272
pubmed: 30837708
Aging (Albany NY). 2022 Dec 13;14(23):9393-9422
pubmed: 36516485
Neuromuscul Disord. 2018 Jan;28(1):87-99
pubmed: 29221629
Nat Rev Rheumatol. 2018 May;14(5):269-278
pubmed: 29651121
Skelet Muscle. 2020 Jul 6;10(1):19
pubmed: 32624006
Brain. 2019 Sep 1;142(9):2590-2604
pubmed: 31326977
Skelet Muscle. 2021 Jul 1;11(1):16
pubmed: 34210364
Nat Commun. 2021 Feb 17;12(1):1088
pubmed: 33597522
Nat Rev Rheumatol. 2020 Jan;16(1):11-31
pubmed: 31792399
Neurobiol Aging. 2010 Jul;31(7):1205-14
pubmed: 18823681
Mol Immunol. 2017 Sep;89:2-9
pubmed: 28601357
BMC Immunol. 2008 Jul 31;9:43
pubmed: 18671865
Front Physiol. 2019 Aug 21;10:1074
pubmed: 31496956
Nat Cell Biol. 2015 Sep;17(9):1205-17
pubmed: 26280535
Aging Cell. 2021 May;20(5):e13344
pubmed: 33939265
Genomics. 1992 Oct;14(2):220-4
pubmed: 1427836
Sci Rep. 2020 Oct 8;10(1):16772
pubmed: 33033277
Am J Physiol Cell Physiol. 2021 Aug 1;321(2):C330-C342
pubmed: 34191625
Cell Rep. 2021 Aug 31;36(9):109634
pubmed: 34469740
J Biol Chem. 2010 Feb 19;285(8):5258-65
pubmed: 20040604
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Cell Rep. 2019 Oct 29;29(5):1082-1098.e10
pubmed: 31665626
Cell Rep. 2017 Nov 28;21(9):2348-2356
pubmed: 29186674
Diagnostics (Basel). 2022 Sep 25;12(10):
pubmed: 36291998
Trends Mol Med. 2022 Jan;28(1):8-11
pubmed: 34750068
Nat Commun. 2020 Dec 11;11(1):6375
pubmed: 33311457
Sci Rep. 2020 Jan 14;10(1):229
pubmed: 31937892
EBioMedicine. 2019 Jun;44:489-501
pubmed: 31221584

Auteurs

Christopher Nelke (C)

Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

Christina B Schroeter (CB)

Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

Lukas Theissen (L)

Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

Corinna Preusse (C)

Department of Neuropathology, Charité-University Medicine Berlin, Bonhoefferweg 3, 10117, Berlin, Germany.

Marc Pawlitzki (M)

Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

Saskia Räuber (S)

Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

Vera Dobelmann (V)

Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

Derya Cengiz (D)

Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

Felix Kleefeld (F)

Department of Neurology, Charité-University Medicine Berlin, Bonhoefferweg 3, 10117, Berlin, Germany.

Andreas Roos (A)

Department of Neuropediatrics, Developmental Neurology and Social Pediatrics, Centre for Neuromuscular Disorders in Children, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Benedikt Schoser (B)

Friedrich Baur Institute at the Department of Neurology, LMU University Hospital, LMU Munich, 80336, Munich, Germany.

Anna Brunn (A)

Institute of Neuropathology, Heinrich Heine University, University Hospital of Düsseldorf, Düsseldorf, Germany.

Eva Neuen-Jacob (E)

Institute of Neuropathology, Heinrich Heine University, University Hospital of Düsseldorf, Düsseldorf, Germany.

Jana Zschüntzsch (J)

Department of Neurology, University Medical Center Göttingen, Robert-Koch-Str. 40, Göttingen, Germany.

Sven G Meuth (SG)

Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

Werner Stenzel (W)

Department of Neuropathology, Charité-University Medicine Berlin, Bonhoefferweg 3, 10117, Berlin, Germany.

Tobias Ruck (T)

Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany. Tobias.Ruck@med.uni-duesseldorf.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH